Aiman Abdel Malek Net Worth

The estimated Net Worth of Aiman Abdel Malek is at least $12.1 Million dollars as of 12 March 2019. Aiman Malek owns over 27,349 units of Insulet stock worth over $11,691,886 and over the last 9 years Aiman sold PODD stock worth over $371,989.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Aiman Malek PODD stock SEC Form 4 insiders trading

Aiman has made over 9 trades of the Insulet stock since 2018, according to the Form 4 filled with the SEC. Most recently Aiman exercised 27,349 units of PODD stock worth $1,014,374 on 12 March 2019.

The largest trade Aiman's ever made was exercising 27,349 units of Insulet stock on 12 March 2019 worth over $1,014,374. On average, Aiman trades about 1,988 units every 19 days since 2016. As of 12 March 2019 Aiman still owns at least 51,341 units of Insulet stock.

You can see the complete history of Aiman Malek stock trades at the bottom of the page.

What's Aiman Malek's mailing address?

Aiman's mailing address filed with the SEC is C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA, MA, 01821.

Insiders trading at Insulet

Over the last 17 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman, and Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.

What does Insulet do?

insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down

Complete history of Aiman Malek stock trades at Insulet

Insulet executives and stock owners

Insulet executives and other stock owners filed with the SEC include:

• Shacey Petrovic,
  President, Chief Executive Officer, Director
• Wayde McMillan,
  Chief Financial Officer, Executive Vice President, Treasurer
• Charles Alpuche,
  Chief Operating Officer, Executive Vice President
• Bret Christensen,
  Executive Vice President and Chief Commercial Officer
• John Kapples,
  Senior Vice President, General Counsel, Secretary
• Shacey Petrovic,
  Pres, CEO & Director
• Michael Spears,
  Senior Vice President - Regulatory Affairs and Compliance
• Charles Alpuche,
  Exec. VP & COO
• Wayde D. McMillan,
  Exec. VP,CFO & Treasurer
• Bret Christensen,
  Exec. VP & Chief Commercial Officer
• Dan Manea,
  Sr. VP & Chief HR Officer
• Corinne Nevinny,
  Independent Director
• timothy Scannell,
  Independent Chairman of the Board
• James Hollingshead,
  Independent Director
• David Lemoine,
  Independent Director
• Sally Crawford,
  Independent Director
• Jessica Hopfield,
  Independent Director
• Michael Minogue,
  Independent Director
• John Fallon,
  Independent Director
• Deborah Gordon,
  Vice President - Investor Relations and Corporate Communications
• Wayne Frederick,
  Director
• Eric Benjamin,
  Senior Vice President, Innovation and Strategy
• John Wodick Kapples,
  Sr. VP, Sec. & Gen. Counsel
• Michael Spears,
  Sr. VP of Regulatory Affairs & Compliance
• Angela Geryak Wiczek,
  Sr. Director of Corp. Communications
• Lauren Budden,
  VP, Chief Accounting Officer & Controller
• David Colleran,
  SVP, Secretary and GC
• Regina O Sommer,
  Director
• Michael L Levitz,
  CFO
• Bradley A Thomas,
  EVP Human Resources
• Joseph S Zakrzewski,
  Director
• Daniel J Levangie,
  Director
• Luciana Borio,
  Director
• James C Mullen,
  Director
• John Garibotto,
  Vice President of Research
• Luis Malave,
  Chief Operating Officer
• Aiman Abdel Malek,
  SVP, Advanced Technology
• Ruthann De Pietro,
  Vice President of Quality
• Patrick J Sullivan,
  President & CEO
• Ross A Md Jaffe,
  Director
• Carsten Boess,
  Chief Financial Officer
• David A Howe,
  VP of Human Resources
• Jason Ng,
  Vice President of Asian Operat
• W Mark Lortz,
  Director
• Steven Sobieski,
  Director
• William D Iii Arthur,
  V.P. of Business Development
• Peter Devlin,
  Chief Commercial Officer
• Brian K Roberts,
  Chief Financial Officer
• Lars Boesgaard,
  Vice President of Finance
• Shawna Gvazdauskas,
  Vice President of Sales
• R Anthony Diehl,
  General Counsel
• Gary Eichhorn,
  Director
• Kevin Schmid,
  Vice President Manufacturing
• John L Brooks,
  10% owner
• Charles T Liamos,
  Director
• Allison Dorval,
  Chief Financial Officer
• Tracey Haas Wielinski,
  VP, Global Regulatory, CA, QA
• William Patrick Ryan,
  Chief Operating Officer
• Duane De Sisto,
  President and CEO
• Advisors Llc Orbimed,
  Director
• Andrew Suchoff,
  Chief Human Resources Officer
• Venture Capital I Lpversant...,
  
• Venture Partners Iii Llc Prism,
  10% owner
• Jonathan Silverstein,
  Director
• Venture Partners Iii A Lp P...,
  10% owner
• Venture Partners Iii Lp Prism,
  10% owner
• Venture Partners Iii A Lp P...,
  
• De Bord Alison Peyromaure,
  Director
• Capital Management Inc Pequot,
  
• Investment Partners Iii Lp ...,
  10% owner
• Stephen Bubrick,
  Vice President of Customer
• William M Seifert,
  10% owner
• Gordon E Nye,
  10% owner
• Samuel D Colella,
  
• Jefferey Smith,
  Vice President of Marketing
• Robert Campbell,
  Vice President for Clinical
• Dan Manea,
  SVP, Chief HR Officer
• Prem Singh,
  SVP, Global Operations
• Timothy C. Stonesifer,
  Director
• Flavia Pease,
  Director
• Elizabeth H Weatherman,
  Director
• Lauren Budden,
  Group VP, CAO and Controller
• Laetitia Cousin,
  SVP, Reg, Quality & Compliance
• Mark N Field,
  SVP & Chief Technology Officer
• Ana Maria Chadwick,
  EVP, CFO & Treasurer